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Systemic embolization has been reported in up to 40% of
patients with left atrial myxoma, half of them with cere-
bral involvement. However, development of intracerebral
embolization associated with parenchymal seeding of the
myxoma emboli is an extremely rare complication, with
only 36 histologically diagnosed cases reported in the pub-
lished literature. We describe a 69-year-old woman who
arrived at the emergency service with hemiparesis associ-
ated with drug-resistant epilepsy and a medical history of
resection of a left atrial myxoma 10 months previously.
Cranial computed tomography revealed multiple large
lesions of heterogeneous density and cystic components in
the occipital lobes and posterior fossa parenchyma. Histo-
pathological analyses after stereotactic biopsy of the occip-
ital lesion revealed infiltrative myxoma cells with benign
histological findings and uniform expression of calretinin
similar to that of the primary cardiac myxoma. Additional
immunohistochemical studies confirmed brain parenchy-
mal seeding of the myxoma cells with strong expression of
interleukin-6 (IL-6) and focal expression of matrix
metalloproteinases-2 (MMP-2). Here, we discuss the clini-
copathological features of intracerebral embolization of
left atrial myxomas associated with progressive parenchy-
mal seeding of the tumor emboli and the potential patho-
genic role of IL-6 and MMPs.
Key words: left atrial myxoma, embolus, interleukin-6,
MMP-2, MMP-9.
INTRODUCTION
Cardiac myxoma is the most frequent primary cardiac
tumor and comprises approximately 70% of primary neo-
plasms in the heart.1 Clinically, cardiac myxoma has a
wide presentation, ranging from constitutional symptoms
to occlusive or embolic events.2 Within this broad clinical
spectrum, embolic events represent the hazardous mani-
festation of the disease, and are usually caused by tumor
fragments or even complete detachment of the tumor.3–6
Systemic embolization occurs in approximately 30–40%
of patients with cardiac myxoma.7,8 As 75–80% of the
tumors arise in the left atrium, approximately half of the
embolic events may affect the central nervous system
(CNS).9 The neurological manifestation of cerebral embo-
lization depends on whether embolic tumor cells remain
intraluminal, leading to ischemic stroke, invade the vessel
wall, resulting in intracranial aneurysms, or, in rare cir-
cumstances, transgress the vessel wall, leading to brain
parenchymal seeding.10
Factors related to the intracranial dissemination of left
cardiac myxomas remain unidentified.11 Some studies sug-
gest a positive correlation between interleukin-6 (IL-6),
matrix metalloproteinase (MMP)-2, and MMP-9, and
increased risk of embolic events and intracranial aneurysms
in left cardiac myxoma patients.12–14 However, the role of
MMPs and IL-6 in the parenchymal seeding of the tumor
emboli remains unknown.
In this article, we describe a case of cerebral and cerebel-
lar embolization with parenchymal seeding and high expres-
sion of IL-6 and MMP-2 after surgical resection of a left
atrial myxoma. Moreover, we summarize a detailed review
of the literature on intracranial embolization associated with
parenchymal seeding, focusing on the potential pathogenic
role of IL-6 and MMPs.
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CLINICAL SUMMARY
A 69-year-old woman with a medical history of drug-
resistant epilepsy for the past four months was admitted to
the emergency service with acute left-side hemiparesis and
distal tremor in both the hands. Ten months prior, she had
undergone total excision of a sporadic left atrial myxoma at
another institution. A deeper analysis of her medical his-
tory revealed repeated recurrent ischemic strokes several
months before the heart surgery. No cardiac lesion was
detected by echocardiography. Biochemical tests revealed
high levels of C-reactive protein (4.3 mg/dL) and lactate
dehydrogenase (538 U/L) in blood. Other tests, such as
complete blood counts and metabolic panel, were normal.
Cranial computed tomography (CT) revealed cortical
and subcortical hyperdense nodules surrounded by the
vasogenic edema zone in the posterior fossa and cerebral
hemispheres. Those lesions were predominantly located in
the frontal, occipital, and cerebellar regions and were ini-
tially suspected as hemorrhagic events (Fig. 1). No mag-
netic resonance imaging (MRI) studies were performed
due to unavailability of equipment. A stereotactic biopsy
of the right occipital lesion was performed. The patient,
with large and multiple intracranial lesions, died 30 months
after initial cardiac surgery.
PATHOLOGICAL FINDINGS
The histologic findings showed brain parenchyma with
hemorrhagic areas surrounded by abundant mucoid matrix
containing sparse spindle-shaped or stellate cells. Tumor
cells had oval nuclei and eosinophilic cytoplasm without
nuclear pleomorphism or mitosis (Fig. 2). Immunohisto-
chemical analyses confirmed parenchymal seeding of the
myxoma cells with strong expression of calretinin
(Fig. 3A). Multiple old hemorrhagic foci with clusters of
hemosiderophages were also found. Based on these find-
ings, we conclude a diagnosis of intracerebral embolization
of left atrial myxoma associated with large solid
intraparenchymal lesions. Moreover, aiming to assess the
role of the IL-6 and MMPs, we found high expressions of
IL-6 (Fig. 3B), focal expression of MMP-2 (Fig. 3C), and
negative expression of MMP-9 (Fig. 3D) in the tumor
cells. Double immunohistochemical staining was initially
planned. However, the lack of experience in our country
prevented performing this procedure.
Review of original tissue sections of the surgically treated
primary cardiac tumor revealed a left atrial myxoma with a
papillary pattern, benign histological features, and uniform
expression of calretinin into the myxoma cells (Fig. 4).15
DISCUSSION
We describe a patient with intracerebral embolization of
left atrial myxoma associated with large parenchymal
lesions. Here, we have confirmed that IL-6 and MMP-2
were expressed in intracranial embolic myxoma cells.
Fig. 1 CT findings of the brain. Axial images display multiple
hyperdense nodules in cortical and subcortical regions of the cer-
ebellum (A) and the frontal and occipital (B) lobes as well as
subsequent hydrocephalus.
Fig. 2 Histological findings on the metastatic brain tumor biopsy
specimen sections stained with HE. (A) The tumor shows abundant
lepidic cells in a myxoid stroma infiltrating brain parenchyma in a
bleeding background. (B) The tumor cells exhibit nuclear pleomor-
phism and mitotic figures (B). Scale bars: 100 μm (A), 50 μm (B).
Fig. 3 Immunohistochemical observations on the metastatic
brain tumor biopsy specimen sections stained for calretinin (A),
IL-6 (B), MMP-2 (C), and MMP-9 (D). The tumor cells are
immunoreactive for calretinin (A), IL-6 (B), and MMP-2 (C).
MMP-9 immunoreactivity is detected only in inflammatory cells
but undetectable in the tumor cells (D). Scale bars: 50 μm (A-D).
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Cardiac myxomas are benign tumors usually located in
the left atrium and can embolize to several extracardiac
tissues. Two gross subtypes of cardiac myxomas have been
described: the solid type and the villous type. The villous-
type tumors have an irregular, often friable, and papillary
surface, as observed in our case. Immunohistochemical
studies revealed uniform expression of calretinin in nearly
all cardiac myxoma cases.15 The brain is the most frequent
embolization site.1 Neuroimaging studies have demon-
strated that ischemic infarction events are the most fre-
quent neurological findings (76.0–88.8%) in patients
harboring left atrial myxomas with neurological manifesta-
tions.6,16 In contrast, the exact prevalence of late neurolog-
ical complications in these patients is unknown because
long-term studies evaluating the likelihood of delayed neu-
rological complications have not been conducted. The larg-
est single-center study, by Brinjikji et al., in 47 patients
treated for left atrial myxoma, reported that intracranial
aneurysm and extravascular “metastasis” represented infre-
quent neuroimaging findings during the follow up of these
patients (observed in 14.9% and 4.3% of cases, respec-
tively).17 However, Zhang et al. followed 12 patients treated
for left atrial myxoma with predominant neurological mani-
festations. They found that eight (67%) patients had multi-
ple intracranial aneurysm, and that six (50%) patients
exhibited extravascular “metastasis”.18
Although the mechanisms of embolization of a benign
tumor and metastasis of an invasive malignancy are funda-
mentally different, the appearance of multiple lesions at a
distant site in the setting of a cardiac myxoma has occa-
sionally been referred to (erroneously) in the literature as
“metastasis.”17,18 Since the first description made by
Rankin et al., in 1978,19 our comprehensive review rev-
ealed 36 histologically established cases of intracerebral
embolization associated with parenchymal brain invasion
from a benign left atrial myxoma (Table 1).10,14,18–51 A
careful review of the cases confirmed that three patients
have been reported twice,14,19,20,23,24,28 six patients had
unavailable histological proof,37,52–56 and four apparent
primary cardiac sarcomas were erroneously reported as a
cardiac myxoma.57–60 In one case, the original report could
not be located,61 and another report described embolic
myxoma cells in the leptomeninges without evidence of
parenchymal seeding.62
A summary of our review shows that cerebral emboli-
zation associated with parenchymal lesions usually occurs
in adults of mean age of 47.6  14.6 (range 15–70) years.
There is a clear femal predominance (male:femal = 1:2).
This rare condition might occur many years before, simul-
taneously with, or many years after the surgical excision of
the primary tumor. Most patients (74.3%) developed
intracerebral embolization several months after re-
section of the cardiac tumor (from 4 to 144 months), and
in around 77.8%, multiple brain regions were involved.
Left atrial myxomas preferentially lodge in the middle
cerebral artery system.63 Thus, parietal and occipital lobes
are the most affected regions (91.6%). Moreover, the
bone 19,35,46 and the skin 23,50 can be simultaneously
involved. The most common clinical presentation of these
patients was seizures (37.1%), followed by headache
(31.4%), and hemiparesis (20%). However, unusual pre-
sentations such as gait disorders 37,42,50 and visual distur-
bances25,27,43 have also been reported. In addition, the
high frequency of intracranial aneurysms (75%) in these
patients suggests that invasion and proliferation of myx-
oma cells into the vessel wall might represent a previous
step to brain parenchymal seeding.
Although cerebral involvement occurred in almost half
of patients with embolic events, it is currently suspected
that only a small portion of distant embolic myxoma may
progress to parenchymal seeding of tumor cells. No risk
factors for the development of this rare complication are
known, but previous history of multiple recurrent neuro-
logical symptoms associated with left atrial myxoma, such
as multiple ischemic strokes or recurrent seizures, may
increase the risk of their appearance. Indeed, up to 70.8%
of patients with late-onset cerebral embolization associ-
ated with parenchymal seeding of the tumor cells pres-
ented with prominent neurologic symptoms during initial
admission. This finding suggests that left atrial myxomas
with previous history of multiple recurrent strokes are
more likely to develop delayed neurological manifesta-
tions during follow up.10,17
Despite multiple parenchymal seeding, the histology of
the primary and embolic tumor infiltrates remains benign
without evidence for malignant transformation. Histologi-
cal evaluation of primary tumor frequently reveals benign
cardiac myxomas with prominent papillary surface projec-
tions.19,24,29,49 Occasionally, cardiac myxofibrosarcomas64
or metastatic adenocarcinomas10,30 might resemble cardiac
myxomas. Based on these circumstances, calretinin
Fig. 4 Histological (A) and immunohistochemical (B) observa-
tions on the metastatic brain tumor biopsy specimen sections sta-
ined with HE (A) and immunostained for calretinin (B). At a
low magnification, villous-type myxoma with numerous friable
fronds is observed (A). At a higher magnification, myxoma cells
are immunoreactive for calretinin (B). Scale bars: 250 μm (A),
50 μm (B). Scale bars: 250 μm (A), 50 μm (B).
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immunohistochemistry is paramount for the proper identi-
fication of embolic cardiac myxomas. In our review, only
seven of 36 cases evaluated calretinin expression in the
infiltrative tumor cells.35,39,43,45,47,49
Although the mechanism of the brain parenchymal
seeding after complete local resection of cardiac myxomas
has not been elucidated, embolic tumor cells might remain
active and invade the wall of the distant vessels.29,35,39,45
Traditionally, the vasa vasorum has been considered a key
element for the embolization of tumor particles. Thus,
small particles entering in the vasa vasorum penetrate the
subintimal tissue, leading to subsequent fragmentation of
the arterial wall.42,45 However, this explanation seems
incomplete because the existence of vasa vasorum has
only been demonstrated in proximal intracerebral
arteries,65,66 and most cerebral emboli occur predomi-
nately in distal intracerebral arteries.6,42,45,67 In contrast,
some authors suggest that the viable tumor particles may
cause progressive disruption of the internal elastic lamina
through a direct transendothelial invasion rather than
hematogenous seeding via vasa vasorum.21,45 Several his-
tological studies have demonstrated that proliferation of
myxoma cells in the arterial wall29,35,39,45 behave like a
nidus for aneurysm formation and an anchor for subse-
quent growth of the extravascular tumor tissue.
The mechanisms by which cardiac myxoma cells pene-
trate the cerebral vessel wall remain unknown. Some
authors have proposed that IL-6 produced by cardiac myx-
oma may play a crucial role in the adhesiveness of myx-
oma cells to cerebral vascular endothelial cells, through
the induction of intercellular adhesion molecule-1 (ICAM-
1) during intracerebral embolization.14 In addition,
Yaguchi et al.68 reported an isolated increase in IL-6 levels
in cerebrospinal fluid (CSF), in contrast to normal serum
levels, in a patient with multiple newly formed intracranial
aneurysms after resection of a cardiac myxoma. These
findings suggest that the high level of IL-6 in CSF reflects
overproduction of IL-6 by embolic myxoma cells in the
intracranial vessel. In light of these previous hypotheses,
14,67–69 we are reporting for the first time the direct evi-
dence for IL-6 expression in embolic tumor cells of a left
atrial myxoma within brain parenchyma.
Increased systemic and local production of IL-6 has
been reported in patients with cerebral aneurysms asso-
ciated with cardiac myxomas.14,67–69 IL-6 stimulates the
gene expression of some MMPs, inclusing MMP-2 and
MMP-9, via the activator protein-1 pathway.70 MMP-9 is
known to break the blood–brain barrier and probably to
facilitate the CNS invasion of myxoma cells.71 Cultured
cells of the embolic myxomas treated with IL-6 had a
higher increase in the activity of both MMP-2 and
MMP-9 than cells from non-embolic myxomas.72 The
proteolytic role of MMPs in expansion of trophoblasts
and cancer cells is well described.73,74 Among the MMP
superfamily, MMP-2 and MMP-9 are essential for the
fragmentation of the internal elastic lamina in both clini-
cal and experimental model studies.75–77 In the present
case, we could demonstrate the expression of MMP-2 in
infiltrative myxoma cells. This finding might suggest that
MMP-2 play a more sustainable role in brain parenchy-
mal seeding of myxoma cells than MMP-9.78,79
Since the first resection of a cardiac myxoma in 1953,
the standard treatment of these tumors has been surgical
removal to reduce the rate of embolic events.80 In con-
trast, the standard management of intracerebral emboliza-
tion after resection of the primary cardiac tumor has not
been well established due to its rarity and variable clinical
course. In our review, similar to the primary cardiac
tumor, surgery was the most frequent therapeutic option
in patients with accessible brain lesions. Radiotherapy has
been frequently conducted for patients with multiple or
progressive lesions, with promising results, although clini-
cal follow up managements are limited.10,32,38,45,47,49,51
Considering that these lesions have persistently active
tumor cells, adjuvant chemotherapy would be a reliable
option to reduce the risk of extracardiac seeding. How-
ever, no previous information on experiences in the man-
agement of this therapeutic option in cardiac myxomas is
available. Currently, surgical resection associated with
radiotherapy is widely used to stabilize the progressive
neurological complications in these patients.32,38,45,47
Further research is still required to understand the
behavior of left atrial myxoma. However, careful attention
should be paid to the neurological symptoms of the
patients to detect delayed neurological complications.
With complete surgical resection of the cardiac myxoma,
strict follow up of the patients should still occur.
Although the left atrial myxoma is a benign tumor, it
has the potential to embolize, especially in the brain.
Cerebral embolization associated with progressive paren-
chymal seeding of the tumor is an extremely rare compli-
cation that may occur several years after surgical removal
of the primary cardiac tumor. The appearance of recurrent
neurological symptoms during the clinical course of left
atrial myxoma may be a risk factor for late-onset neuro-
logical manifestations. Our case supports previous obser-
vations that the expression of IL-6 and MMP-2 in
myxoma cells favors progression of the intracranial
embolic process. Thus, future research is essential to
determine the diagnostic and therapeutic application of
these markers for the tumor.
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